Проблемы особо опасных инфекций (Sep 2017)

DEVELOPMENT OF PHARMACEUTICAL DOSAGE FORM OF ANTI-CHOLERA IMMUNE-ENTEROSORBENT

  • M. V. Ovchinnikova,
  • A. V. Komissarov,
  • E. G. Abramova,
  • M. N. Kireev,
  • A. Yu. Ul’yanov,
  • D. N. Bibikov,
  • M. N. Islyaeva,
  • A. K. Nikiforov

DOI
https://doi.org/10.21055/0370-1069-2017-3-100-104
Journal volume & issue
Vol. 0, no. 3
pp. 100 – 104

Abstract

Read online

Objective of the study is to experimentally substantiate the possibility of production of anti-cholera immune-enterosorbent in the pharmaceutical form of a pill.Materials and methods: experimental antitoxic immune-enterosorbent against cholera, stabilized using cool dehumidification. Residual moisture of enterosorbent lyophilizate was determined by means of Sartorius MA 150 moisture meter. Screen assay of the powders and granulates was performed applying the sieving of bulk material samples through screen set with sieve openings of various sizes. Specification of tap density was carried out with the help of SVM-10 unit. Granulation of specific enterosorbent was done using GPCG 2 LabSystem. The pills were manufactured in tablet press, MiniTabT. The hardness of the pallets was carried out by means of TBH 125 TD tester. The test for friability of the pills was performed in GTA 120.Results and conclusions. Utilization of cellulose microcrystalline and polyvinyl pyrolidone as pharmaceutical aids for granulation of lactose monohydrate is experimentally substantiated. It is established that the obtained granulate with passable values of technological parameters can serve as the basis for pharmaceutical dosage form of specific enterosorbent. Identified has been optimum mass of anti-cholera enterosorbent tablet cores. Demonstrated has been the possibility of Acryl-eze enteric coating application as protective shell of the pills. Studied has been specific activity of the pelleted enterosorbent in vitro, verified is its resistance capacity under conditions modeling gastrointestinal tract. In consequence of the performed trials and tests, technology for the production of antitoxic enterosorbent against cholera – enteric-coated tablet – has been developed. Long-term trials: the storage of the constructed preparation at 4–8°C within 24 months period (the observation time) – have revealed retention of enterosorbent activity, which testifies to its stability and defined the shelf life of specific tableted anti-cholera immune-enterosorbent.

Keywords